🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Earnings Call: SS&C Technologies Posts Record Q3 2023 Revenue, Optimistic About Future Growth

Published 27/10/2023, 14:24
© Reuters.
SSNC
-

SS&C Technologies Holdings (NASDAQ:SSNC) Inc. reported a record Q3 2023 adjusted revenue of $1,366.7 million, marking a 3.4% increase compared to the previous year. The company also achieved its second-highest adjusted consolidated EBITDA at $533.9 million, with an EBITDA margin of 39.1%. The company's financial services retention rate for Q3 2023 was 97.3%, the highest in its history.

Key takeaways from the earnings call include:

  • SS&C Technologies generated cash from operating activities of $826.7 million for the nine months ended September 30th, up 8.1% from the previous year.
  • The company bought back 1.7 million shares for $96.9 million and raised its common stock quarterly dividend by 20% to $0.24 per share.
  • SS&C paid down $54.7 million in debt, bringing its net leverage ratio to 3.18 times consolidated EBITDA.
  • Significant savings were achieved through the deployment of Blue Prism digital workers, resulting in a 7% reduction in headcount.
  • The Alternatives, Intralinks, and Retirement businesses showed strong growth, with Alternatives growing 8.4% in the quarter and Intralinks growing over 10%.
  • The company expects Q4 2023 revenue to be in the range of $1,370 million to $1,410 million and full-year 2023 revenue to be in the range of $5,463.5 million to $5,503.5 million.

During the earnings call, SS&C Technologies expressed confidence in its ability to drive high EBITDA, pay down debt, and buy back stock. The company also highlighted its focus on innovation and competition against larger financial institutions. In terms of mergers and acquisitions, SS&C expressed interest in the Australian, Canadian, and UK markets, with plans to potentially spend $100 million on acquisitions in the coming months.

The company also provided updates on its healthcare business, mentioning its stabilization and the opportunities in the segment. It plans to put tens of millions of lives under DomaniRx by the first quarter of 2024. In terms of their healthcare clientele, major clients include Aetna, CVS, Cigna (NYSE:CI), and Anthem (NYSE:ELV).

SS&C Technologies was recognized by Waters (NYSE:WAT) Technology and Gartner for its products and services. The company also highlighted its recent SS&C Deliver Conference, where it showcased over 40 solutions focused on AI and robotics process automation. The company concluded the call by expressing appreciation for the attendees and its plans to provide updates after the end of the year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.